Genmab A/S (GMAB)
Genmab A/S reported revenue of 925M USD for the quarter ending 30 June 2025.
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
filled in.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in USD.
The same series drawn ›
As last reported
The newest period the filing supports for each figure, in USD.
| Figure | Period | Amount | Year on year |
|---|
| Revenue |
Q2 '25 · ending 30 June 2025 |
925M |
— |
| Gross Profit |
Q2 '25 · ending 30 June 2025 |
868M |
— |
| Operating Income |
Q2 '25 · ending 30 June 2025 |
360M |
— |
| Net Income |
Q2 '25 · ending 30 June 2025 |
336M |
— |
| Cost of Revenue |
Q2 '25 · ending 30 June 2025 |
57M |
— |
| EPS |
2025 · ending 31 December 2025 |
15.37 |
-12.3% |
Revenue and profit by financial year
As filed, in USD. A year the filing does not support is not listed.
| Year | Ending |
Revenue | Operating Income | Net Income | Free Cash Flow |
|---|
| 2025 | 2025-12-31 |
3.7B | 1.1B | 963M | 1.1B |
|---|
| 2024 | 2024-12-31 |
3.1B | 972M | 1.1B | 1.1B |
|---|
| 2023 | 2023-12-31 |
2.4B | 772M | 631M | 1B |
|---|
Every period
Revenue Quarterly
| Period | Ending | Revenue |
|---|
| Q2 '25 | 2025-06-30 | 925M |
|---|
| Q2 '24 | 2024-06-30 | 779M |
|---|
Gross Profit Quarterly
Revenue minus cost of sales. This filer tags no gross profit of its own..
| Period | Ending | Gross Profit |
|---|
| Q2 '25 | 2025-06-30 | 868M |
|---|
| Q2 '24 | 2024-06-30 | 751M |
|---|
Operating Income Quarterly
| Period | Ending | Operating Income |
|---|
| Q2 '25 | 2025-06-30 | 360M |
|---|
| Q2 '24 | 2024-06-30 | 236M |
|---|
Net Income Quarterly
| Period | Ending | Net Income |
|---|
| Q2 '25 | 2025-06-30 | 336M |
|---|
| Q2 '24 | 2024-06-30 | 203M |
|---|
Cost of Revenue Quarterly
| Period | Ending | Cost of Revenue |
|---|
| Q2 '25 | 2025-06-30 | 57M |
|---|
| Q2 '24 | 2024-06-30 | 28M |
|---|
EPS Annual
The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.
| Period | Ending | EPS |
|---|
| FY25 | 2025-12-31 | 15.37 |
|---|
| FY24 | 2024-12-31 | 17.53 |
|---|
| FY23 | 2023-12-31 | 9.58 |
|---|